Adocia S.A.S. American Depositary Receipt (ADOCY)

Overview

Adocia SA is a formidable entity in the biotechnological sector, focusing primarily on the clinical stage development of innovative formulations of pre-approved therapeutic proteins and peptides. Situated in the realm of diabetes and other metabolic diseases, Adocia leverages its proprietary BioChaperone technological platform to enhance the molecular delivery of therapeutic proteins. This avant-garde approach underpins the company's quest to address the unmet medical needs within this sphere. Established in the year 2005 and stationed in Lyon, France, Adocia not only exemplifies innovation but also demonstrates a commitment to global health through its strategic alliances, notably with Tonghua Dongbao Pharmaceutical Co., Ltd. This partnership is aimed at fostering the development and commercialization of its hallmark insulin formulations in pivotal markets across Asia and the Middle East, reflecting Adocia's strategic intent to broaden its global footprint and impact.

Products and Services

• BioChaperone Lispro U100 and U200:

  These ultrarapid insulin formulations, based on rapid insulin lispro, are designed to significantly accelerate insulin absorption post-injection, thereby promoting a more efficient glucose regulation and mimicking natural insulin secretion patterns closely.

• BioChaperone Combo:

  A pioneering combination that marries the long-acting insulin glargine with the rapid-acting insulin lispro, aiming to simplify diabetes management by enabling both basal and prandial insulin delivery in a single injection.

• BioChaperone LisPram:

  This inventive combination melds prandial insulin with pramlintide to optimize glycemic control by enhancing the effects of insulin and mimicking the natural hormonal response to food intake.

• BioChaperone Glucagon:

  An aqueous formulation of human glucagon poised to transform the emergency treatment of hypoglycemia by facilitating easier and more rapid administration during critical episodes.

• M1Pram:

  A next-generation metabolic management solution that synergistically combines the metabolite of insulin glargine with pramlintide, designed to offer superior postprandial glucose control.

• AdoShell Islets:

  A groundbreaking preclinical project involving an implant containing islets of Langerhans aimed at promoting insulin independence in severe cases of diabetes, marking a significant stride towards curative therapies.

• AdOral Sema:

  This ambitious endeavor seeks to revolutionize semaglutide delivery by facilitating oral administration, thereby improving patient compliance and widening the therapeutic reach of this potent antidiabetic agent.

• BioChaperone GluExe:

  In a quest to address both diabetes and obesity, this combination therapy merges glucagon and exenatide to exploit their complementary mechanisms, potentially redefining the therapeutic landscape for these intertwined metabolic disorders.